Abstract
ORI-9020, a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA (P </= 0.001). Levels of HBeAg and HBsAg in serum and of HBcAg in liver were not affected by treatment. A minimal effective dosage was determined to be between 1.6 and 0.5 mg/kg of body weight/day, which was similar to that observed for adefovir dipivoxil.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / pharmacology*
-
Blotting, Southern
-
DNA, Viral / blood
-
Hepatitis B Core Antigens / blood
-
Hepatitis B Surface Antigens / blood
-
Hepatitis B e Antigens / blood
-
Hepatitis B virus / drug effects*
-
Hepatitis B virus / genetics*
-
Injections, Intraperitoneal
-
Liver / metabolism
-
Liver / virology
-
Male
-
Mice
-
Mice, Transgenic
-
Oligonucleotides / administration & dosage
-
Oligonucleotides / pharmacology
-
RNA, Viral / metabolism
Substances
-
Antiviral Agents
-
DNA, Viral
-
Hepatitis B Core Antigens
-
Hepatitis B Surface Antigens
-
Hepatitis B e Antigens
-
ORI 9020
-
Oligonucleotides
-
RNA, Viral